Drug intelligence / Profile preview

PSB109

Development stage: Unknown
Lead developer: Qilu Puget Sound Biotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PSB109 is a monoclonal antibody developed by Sound Biologics that targets the colony-stimulating factor 1 receptor (CSF1R). It is designed to modulate the tumor microenvironment by targeting macrophage biology, specifically tumor-associated macrophages (TAMs), to support anti-tumor immune responses. By inhibiting the CSF1R signaling pathway, PSB109 aims to reduce the immunosuppressive nature of the tumor microenvironment, potentially enhancing the effectiveness of other cancer treatments. It is currently in Phase 1 development for the treatment of solid tumors.

Targets

CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on PSB109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB109.

Explore the full profile